Increasing both specificity and sensitivity of SARS-CoV-2 antibody tests by using an adaptive orthogonal testing approach

Running head: Orthogonal testing in SARS-CoV-2 antibody detection

Thomas Perkmann[1], Nicole Perkmann-Nagele[1], Maria Oszvar-Kozma[1], Thomas Koller[1], Marie-Kathrin Breyer[2], Robab Breyer-Kohansal[2], Otto C Burghuber[3], Sylvia Hartl[2,3], Daniel Aletaha[4], Daniela Sieghart[4], Peter Quehenberger[1], Rodrig Marculescu[1], Patrick Mucher[1], Astrid Radakovics[2], Robert Strassl[1], Gerda Leitner[5], Oswald F Wagner[1], Christoph J Binder[1], and Helmuth Haslacher[1*]

[1]Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria
[2]Department of Respiratory and Critical Care Medicine and Ludwig Boltzmann Institute for Lung Health, Otto Wagner Hospital, Vienna, Austria
[3]Sigmund Freud University, Medical School and Ludwig Boltzmann Institute for Lung Health, Vienna, Austria
[4]Divison of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria
[5]Department of Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Vienna, Austria

*Please address all correspondence to:
Helmuth Haslacher, LECT MD PhD MSc BSc BA
Medical University of Vienna, Department of Laboratory Medicine
Waehringer Guertel 18-20, A-1090 Vienna
Phone: +43 1 40400 53190
Fax: +43 1 40495 15547
E-Mail: helmuth.haslacher@meduniwien.ac.at

Key words:
SARS-CoV-2; serology; specificity; sensitivity; seroprevalence; cut-off reduction; orthogonal testing

List of abbreviations:

COVID-19	Coronavirus disease 2019
SARS-CoV-2	Severe Acute Respiratory Syndrome Coronavirus 2
RT-PCR	Reverse transcriptase-polymerase chain reaction
ECLIA	Electrochemiluminescence assay
95% CI	95% confidence interval
CMIA	Chemiluminescent microparticle immunoassay
CLIA	Chemiluminescence immunoassay
PPV	Positive predictive value
NPV	Negative predictive value

ABSTRACT

Background

SARS-CoV-2 antibody tests have undergone a remarkable improvement in performance. However, due to the low seroprevalence in several areas, very high demands are made on their specificity. Furthermore, the low antibody-response in some individuals requires high test sensitivity to avoid underestimating true seroprevalence. Optimization of testing has been reported through lowering manufacturer cut-offs to improve SARS-CoV-2 assay sensitivity or by combining two tests to improve specificity at the cost of sensitivity. However, these strategies have thus far been used in isolation of each other.

Methods

To increase sensitivity, cut-offs of three commercially available SARS-CoV-2 automated assays (Roche, Abbott, and DiaSorin) were reduced according to published values in a pre-pandemic specificity cohort (n=1117) and a SARS-CoV-2 positive cohort (n=64). All three testing systems were combined in an orthogonal approach with a confirmatory test, which was one of the remaining automated assays or one of two commercial ELISAs directed against the spike protein receptor binding-domain (RBD) or the nucleocapsid antigen (NP).

Results

The modified orthogonal test strategy resulted in an improved specificity of at least 99.8%, often even 100%, in all 12 tested combinations with no significant decline in sensitivity. In our cohort, regardless of whether the assays were used for screening or confirmation, combining Roche and Abbott delivered the best overall performance (+~10% sensitivity compared to the single tests and 100% specificity).

Conclusion

Here we propose a novel orthogonal assay strategy that approaches 100% specificity while maintaining or even significantly improving the screening test's sensitivity.

Introduction

Serological tests detecting SARS-CoV-2 specific antibodies became available shortly after the beginning of the COVID-19 pandemic. Over the last few months, SARS-CoV-2 serology has experienced incredible diversity and technical development. Only weeks after the first ELISA protocol for SARS-CoV-2 antibody testing had been made publicly available (1), several fully automated serologic tests received emergency-use authorization by the FDA (2).

It should be noted that these tests can perform very different diagnostically, which has been described in detail recently (3-15). Due to the continuing overall low seroprevalence of SARS-CoV-2 (16), the need for highly specific (≥99.5%) test systems to provide adequate positive predictive values has become evident (17). Additionally, contrary to the manufacturers' data and the first publications on this subject, the test systems have not proven sufficiently sensitive (4-6, 11, 18, 19). This discrepancy could be explained because the COVID-19 positive cohorts in the validation studies were mainly hospitalized patients and not cases with mild to moderate or even asymptomatic disease (20). However, there is increasing evidence that, especially in non-hospitalized cases with RT-PCR confirmed SARS-CoV-2 infection, very low levels of specific antibodies can be observed frequently (21-24). Inadequate antibody responses can eventually lead to a negative result when the manufacturers' cut-offs are applied, resulting in suboptimal sensitivities of the test systems.

Recently, an increasing number of publications have suggested two-test algorithms for SARS-CoV-2 serology (11, 15, 19, 25, 26). However, standard two-test algorithms aim to increase specificity, not sensitivity. This strategy is already used in the serodiagnosis

of other infectious diseases and was recently also recommended by U.S. national public health officials to overcome the specificity issue. In the case of SARS-CoV-2, false-positive samples are usually not simultaneously reactive in different test systems (4, 15). Thus, an orthogonal test approach, in which positive results are confirmed with another test, can maximize specificity by excluding false-positive results.

The disadvantage of this test strategy, which was recently shown in a study for the SARS-CoV-2 antibody tests from Abbott, Roche, and DiaSorin (19), is that the gain in specificity usually comes at the expense of sensitivity and therefore increases the number of false negatives of individual tests. Thus, depending on the seroprevalence, undesired changes from over- to underestimating the actual number of SARS-CoV-2 seropositive samples may occur. To overcome this limitation, a fundamentally modified orthogonal test strategy was necessary: by maximally reducing the cut-offs of the individual tests, sensitivity was markedly increased, and consequently reduced specificity was compensated by orthogonal testing.

In the present work, we show for the first time an orthogonal test algorithm based on real-life data for the SARS-CoV-2 antibody tests of Roche, Abbott, DiaSorin, and two commercial SARS-CoV-2 ELISAs modified according to Krammer et al. (27) intending to maximize both specificity and sensitivity at the same time.

Methods

Study design and patient cohorts

Samples used in this non-blinded prospective cross-sectional study were either left-over materials from the diagnostic process (N=13) or derived from the MedUni Wien Biobank, a facility specialized in the preservation and storage of human biomaterial, which operates within a certified quality management system (ISO 9001:2015) (28).

As described before (4), samples from collections established before 01.01.2020 were used as a specificity cohort: a cross-section of the Viennese population, LEAD study (29), pre-selected for samples collected between November and April to enrich for seasonal infections (n=494); a collection of healthy voluntary donors (n= 265); a disease-specific collection of samples from patients with rheumatic diseases (n=358).

The SARS-CoV-2 positive cohort (n=64 samples from n=64 individuals) consisted of samples from 38 convalescent donors from the MedUni Wien Biobank (29 were PCR-confirmed cases, 9 were close contacts of them), 19 PCR-confirmed in- or outpatients of the General Hospital Vienna and seven convalescent plasma donors from the Department of Blood Group Serology and Transfusion Medicine. Of the overall cohort, 42 presented with mild to moderate symptoms, 4 reported severe symptoms, 13 were admitted to the Intensive Care Unit (ICU), and 5 donors were asymptomatic. Symptom onset to analysis time was determined by a questionnaire in convalescent donors and by reviewing individual health records in patients. For asymptomatic donors (n=5), SARS-CoV-2 RT-PCR confirmation to analysis time was used instead. A detailed description of all cohorts was published previously (4). All included participants gave written informed consent to donate their samples for scientific purposes. From patients, only left-over

material from diagnostic procedures was used. The overall evaluation plan conformed with the Declaration of Helsinki as well as relevant regulatory requirements. It was reviewed and approved by the ethics committee of the Medical University of Vienna (1424/2020).

Antibody testing

SARS-CoV-2 specific antibodies were either measured according to the manufacturers' instructions on three different automated platforms (Roche, Abbott, DiaSorin) or using enzyme-linked immunosorbent assays (ELISA) manufactured according to the test established by the Krammer Lab (30) (Technoclone Technozym® RBD and Technozym® NP) at the Department of Laboratory Medicine, Medical University of Vienna.

In brief, the Roche Elecsys® Anti-SARS-CoV-2 assay detects total antibodies against the nucleocapsid (NC) antigen in a sandwich electrochemiluminescence immunoassay (ECLIA) on a cobas® e801 analyzer (Roche Diagnostics, Rotkreuz, Switzerland). According to the manufacturer, results exceeding 1.000 COI are considered positive. The Abbott SARS-CoV-2 assay detects IgG-antibodies against NC in a chemiluminescence microparticle assay (CMIA) on Abbott ARCHITECT® i2000sr platforms (Abbott Laboratories, Chicago, USA). The cut-off suggested by the manufacturer is 1.40 index (S/C). The DiaSorin LIAISON® SARS-CoV-2 S1/S2 IgG test detects IgG-antibodies against the S1/S2 domains of the virus' spike protein on LIAISON® XL analyzers (DiaSorin S.p.A., Saluggia, Italy) employing chemiluminescence immunoassays (CLIA). Results >12.0 AU/mL are considered

positive (the manufacturer suggests retesting of borderline results between 12.0 – 15.0 AU/mL; however, this approach is not practicable when using historical samples).

Commercially available ELISAs based on the protocols developed in the Krammer Lab (27) are directed against the nucleoprotein (NP) (Technozym® anti SARS-CoV-2 NP IgG) or the RBD (Technozym® anti SARS-CoV-2 RBD IgG) domain of the spike protein (Technoclone, Vienna, Austria). Calibrators and controls of both tests are traceable to a specific antibody against the SARS-CoV-2 receptor-binding domain (CR3022). These quantitative assays were processed manually according to the manufacturer's instructions. IgG-antibodies were quantified on a Filtermax F5 plate reader (Molecular Devices, San José, USA). The reduced cut-offs for these assays were modeled in-house and set at 4000 U/ml (data not shown). Statistics

Orthogonal testing algorithm

Potential orthogonal testing approaches were identified by a combination of a screening test performed on an automated platform (Roche, Abbott, or DiaSorin) and a confirmation test, which could be one of the remaining automated assays or an ELISA test (Technozym® NP or Technozym® RBD) that can be easily performed without additional large-scale equipment. As suggested in the literature, the cut-off levels for Roche, Abbott, and DiaSorin were reduced to increase sensitivities (3, 10, 31). Values above the higher cut-off (i.e., no false positives above this range) were considered positive without additional confirmation tests. All results that fell between the lower cut-off value and the higher cut-off value were retested with one of the confirmation tests (Figure 1).

Statistical analysis

Unless otherwise indicated, categorical data were given as counts (percentages), and continuous data were presented as median (interquartile range). 95% Confidence Intervals (CI) for sensitivities and specificities were calculated according to Wilson, 95% CI for predictive values were computed according to Mercaldo-Wald unless otherwise indicated. Sensitivities and specificities were compared by z-score testing. All calculations were performed using Analyse-it 5.66 (Analyse-it Software, Leeds, UK).

Results

Conventional orthogonal testing with manufacturers' cut-offs

Using the cut-offs as suggested by the manufacturers in conventional orthogonal test settings (i.e., confirmation of positives by a second, confirmatory test system), a specificity of about 100% (99.9-100%) was obtained for all tested combinations. The sensitivities, on the other hand, reached at most the initial value of the screening test used, but usually decreased significantly (range 70.3 [58.2-80.2] – 84.4 [73.6-91.3]) depending on the confirmatory test used (Supplemental Table 1). Interestingly, for the Roche test, no significant further improvement in specificity could be achieved by orthogonal testing using the cut-offs suggested by the manufacturers, as the initial specificity was already close to 100%. On the other hand, it significantly lost sensitivity in 3 out of 4 tested combinations. Furthermore, of all tested combinations, only the retesting of Abbott results by Roche achieved a statistically significant improvement in specificity while maintaining the screening test's initial sensitivity. In the next step, we aimed to increase sensitivities by lowering the cut-offs for positivity.

Increasing sensitivity of automated SARS-CoV-2 antibody assays by reducing the cut-offs

As suggested in the literature, cut-offs for positivity of automated SARS-CoV-2 antibody assays were lowered to >0.165 COI (Roche) (31), ≥0.55 index (Abbott) (10), and >9.0 AU/mL (DiaSorin) (3), see also Figure 1. As a result, 6 additional samples were correctly identified as positive for Roche, 8 for Abbott, and 4 for DiaSorin (Figure 2 and Supplemental Table 2). Hence, sensitivity increased significantly for all automated assays: Roche +9.4%, Abbott +12.5%, and DiaSorin +6.3% (Table 1). In contrast, the increase in false positives (Roche +15, Abbott +18, and DiaSorin +11) significantly

reduced the specificity of the tests: Roche -1.3%, Abbott -1.6%, DiaSorin -1.0% (Table 1). This loss of specificity caused consistently low positive predictive values at a presumed seroprevalence of 2% (39.6-55.5%). IgG based assays showed strikingly isolated overlaps in false-positive samples: Abbott had one false positive specimen in common with DiaSorin and two matching samples each with the RBD and NP ELISA; DiaSorin shared one more sample with the RBD ELISA. Interestingly, there was no such overlay of false-positive results in the Roche assay with any of the four IgG-based assays tested (Figure 2 and Supplemental Table 2). In the next step, we aimed to restore specificity by an orthogonal testing approach.

Recovery of specificity by an adaptive orthogonal testing approach

All specimens with results between the reduced cut-offs derived from the literature and the high cut-offs (where false positives were no longer expected) in the screening assay were retested with a second method (see retesting range in Figure 2). Of the total 1181 specimens (1117 pre-COVID and 64 post-COVID samples, 5.4% positivity rate), 27 (2.3%) were retested for Roche, 45 (3.8%) for Abbott and 87 (7.4%) for DiaSorin.

The Roche Elecsys® total antibody assay could be combined with all remaining tests to reach a specificity of 100.0% (99.7-100.0), with no false positives left. However, this increase in specificity was not statistically significant compared to the single test approach using the manufacturer's cut-offs, as the initial specificity was already comparably high (99.7%). Simultaneously, sensitivities remained significantly increased when combined with the Abbott, the DiaSorin, and the Technozym® RBD assay (all $p<0.05$).

The Abbott Anti-SARS-CoV-2 IgG test, in contrast, reached 100.0% specificity only when followed by the Roche assay; in the other combinations, it remained slightly below, as a few false-positives persisted (99.8-99.9%). Pairing the Abbott with the Roche assay or the Technozym® RBD ELISA also raised the sensitivity significantly ($p<0.01$).

The specificity of the DiaSorin LIAISON Anti-Sars-CoV-2 IgG assay could be significantly improved (99.9-100.0%) when all samples with results >9.0 AU/mL were retested with any of the remaining assays. However, in all combinations except for that with the Roche assay ($p<0.05$), sensitivity returned to previous levels, but did not further decrease, as it was the case when applying a conventional orthogonal testing algorithm using the manufacturers' cut-offs (results of all combinations are displayed in Table 2).

Selection of the ideal test combination

Orthogonal testing with reduced cut-offs resulted in improved specificity (between 99.8 and 100% specificity) in any of the 12 combinations tested. The greatest increase in specificity was achieved for the DiaSorin assay (from 98.2% to 99.9 or 100%). Besides, when the Roche assay was used as the primary test, all combinations except with the NP ELISA showed a statistically significant gain in sensitivity (from 89.1% to 95.3% or 96.9%). The Roche assay yielded the highest sensitivity increases when used as a confirmatory test (from 84.4% to 96.9% for Abbott and 82.9% to 88.9% for DiaSorin). In our test cohort, Roche and Abbott's combination led to the best overall performance, no matter whether Roche or Abbott was used as a screening or confirmatory test (specificity 100% and sensitivity 96.9%). The second-best solution was achieved using Roche as screening and RBD ELISA or DiaSorin as a confirmatory test (specificity 100%

and sensitivity 95.3%). Table 3 provides an overview of the improvements in specificity and sensitivity of all assay combinations.

Discussion

The detection of specific antibodies can confirm a previous infection with SARS-CoV-2, even if the infection was not diagnosed by PCR or was asymptomatic in the first place. For this reason, serological SARS-CoV-2 testing is the method of choice for estimating the prevalence of previously infected persons and closing the gap between PCR confirmed cases and unreported cases (17). Due to the very variable, but globally still low seroprevalence rates for SARS-CoV-2 (16), high demands are placed on the specificity of the antibody assays (Supplemental Figure 1). Many commercially available SARS-CoV-2 antibody tests do not provide sufficient specificity to achieve acceptable positive predictive values (PPVs), for example at a seroprevalence rate of 1-5% (4, 11).

So far there have been three different approaches to solve the problem of specificity:

a) the use of assays with very high specificity (>99.5%);

b) to increase the pre-testing probability by pre-selecting high-risk populations;

c) the use of conventional orthogonal testing, whereby initial positive results are confirmed by a second method to exclude false positives.

There are indeed already some highly specific assays (14), but their application might not be possible everywhere due to regional differences in availability or lack of technical equipment. This solution, therefore, cannot be implemented in every case. Preselection of populations could lead to a biased picture of the overall situation in seroprevalence studies. A conventional orthogonal test strategy can undoubtedly increase the specificity massively and even bring it very close to 100%, but a decisive disadvantage can arise as recent publications have shown: i.e., a significant loss of sensitivity (19, 26). We

could previously show that the sensitivity of SARS-CoV-2 antibody tests can drop below 90%, especially when non-hospitalized patients are included (4). In the meantime, suboptimal sensitivities of SARS-CoV-2 antibody tests have been described in numerous subsequent publications (4, 7, 12, 32). Thus, an orthogonal test strategy with a certain further loss of sensitivity does not seem appropriate for seroprevalence studies, especially considering the dynamic development of infection rates we are facing. A-priori estimates of the expected prevalence could therefore be misleading. If we experience a shift from low prevalence to high prevalence due to the overall trend of infections or regional clustering ("hot spots"), adequate sensitivity is just as important as adequate specificity of the test system used.

Based on real data related to SARS-CoV-2, which are in principle generalizable for all types of serological tests, we, therefore, propose a entirely new test strategy and thus a fourth approach to solve the problem:

The combination of improved sensitivity through cut-off modeling and an orthogonal test strategy to restore specificity. This algorithm offers the opportunity to significantly improve the overall performance of SARS CoV-2 antibody tests.

For this purpose, the recommended manufacturer cut-offs were reduced according to the results of other independent studies (3, 10, 31). These reduced cut-offs to increase sensitivity are close to the modeled Youden indices, and indeed, although described in completely independent studies, they can obviously be applied to our study collective. Therefore, we anticipate that certain generalizability can be assumed in this context and that cut-offs for other test systems can be modeled in a similar way based on the Youden indices. All 12 combinations tested in the present study (3 screening tests with 4

different confirmatory tests each) achieved specificities of 99.8%-100.0%. Consequently, a significant increase in specificity was achieved for Abbott, and a massive increase in specificity was seen for DiaSorin, due to the very moderate initial specificity of 98.2%. For DiaSorin, this means a doubling of the PPV at an assumed seroprevalence of 2%.

In contrast to a classical orthogonal test approach (19, 26), no statistically significant decrease in sensitivity below the screening test's initial level was detected in any combination tested. However, the combinations Roche + RBD ELISA or Abbott or DiaSorin, as well as Abbott + RBD ELISA or Roche or DiaSorin, and DiaSorin + Roche showed significant increases in sensitivity. In this context, it should be noted that the maximum achievable sensitivity in the orthogonal test approach depends very much on the sensitivity performance of the screening assay. In our study, the Roche test clearly outperformed the DiaSorin test with a substantial difference in initial sensitivity, and reduced cut-offs of the Roche test, allowing for a wider range of inclusion of additional positives. All additional potential false-positives were ruled out by the confirmation tests.

We propose a novel orthogonal test strategy for SARS-CoV-2 serology (but generally applicable to serological testing), which makes it possible to maintain or even significantly improve sensitivity while approaching 100% specificity.

Acknowledgments

We sincerely thank Marika Gerdov, Susanne Keim, Karin Mildner, Elisabeth Ponweiser, Manuela Repl, Ilse Steiner, Christine Thun, and Martina Trella for excellent technical assistance. Finally, we want to thank all the donors of the various study cohorts. Without their voluntary participation in the establishment of the biobanks, this study would not have been possible. There was no external funding received. However, test kits for the Technoclone ELISAs were kindly provided by the manufacturer.

References

1. Stadlbauer D, Amanat F, Chromikova V, Jiang K, Strohmeier S, Arunkumar GA, et al. SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup. Curr Protoc Microbiol. 2020;57(1):e100.

2. Administration USFaD. EUA Authorized Serology Test Performance 2020 [Available from: https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance.

3. Bonelli F, Sarasini A, Zierold C, Calleri M, Bonetti A, Vismara C, et al. Clinical and Analytical Performance of an Automated Serological Test That Identifies S1/S2-Neutralizing IgG in COVID-19 Patients Semiquantitatively. J Clin Microbiol. 2020;58(9).

4. Perkmann T, Perkmann-Nagele N, Breyer MK, Breyer-Kohansal R, Burghuber OC, Hartl S, et al. Side by side comparison of three fully automated SARS-CoV-2 antibody assays with a focus on specificity. Clin Chem. 2020.

5. Charlton CL, Kanji JN, Johal K, Bailey A, Plitt SS, MacDonald C, et al. Evaluation of Six Commercial Mid- to High-Volume Antibody and Six Point-of-Care Lateral Flow Assays for Detection of SARS-CoV-2 Antibodies. J Clin Microbiol. 2020;58(10).

6. Tan SS, Saw S, Chew KL, Wang C, Pajarillaga A, Khoo C, et al. Comparative Clinical Evaluation of the Roche Elecsys and Abbott SARS-CoV-2 Serology assays for COVID-19. Arch Pathol Lab Med. 2020.

7. Tang MS, Hock KG, Logsdon NM, Hayes JE, Gronowski AM, Anderson NW, et al. Clinical Performance of Two SARS-CoV-2 Serologic Assays. Clin Chem. 2020;66(8):1055-62.

8. Weidner L, Gansdorfer S, Unterweger S, Weseslindtner L, Drexler C, Farcet M, et al. Quantification of SARS-CoV-2 antibodies with eight commercially available immunoassays. J Clin Virol. 2020;129:104540.

9. Chan CW, Parker K, Tesic V, Baldwin A, Tang NY, van Wijk XMR, et al. Analytical and Clinical Evaluation of the Automated Elecsys Anti-SARS-CoV-2 Antibody Assay on the Roche cobas e602 Analyzer. Am J Clin Pathol. 2020;154(5):620-6.

10. Lau CS, Oh HML, Hoo SP, Liang YL, Phua SK, Aw TC. Performance of an automated chemiluminescence SARS-CoV-2 IG-G assay. Clin Chim Acta. 2020;510:760-6.

11. Manthei DM, Whalen JF, Schroeder LF, Sinay AM, Li SH, Valdez R, et al. Differences in Performance Characteristics Among Four High-Throughput Assays for the Detection of Antibodies Against SARS-CoV-2 Using a Common Set of Patient Samples. Am J Clin Pathol. 2020.

12. Tang MS, Hock KG, Logsdon NM, Hayes JE, Gronowski AM, Anderson NW, et al. Clinical Performance of the Roche SARS-CoV-2 Serologic Assay. Clin Chem. 2020;66(8):1107-9.

13. Horber S, Soldo J, Relker L, Jurgens S, Guther J, Peter S, et al. Evaluation of three fully-automated SARS-CoV-2 antibody assays. Clin Chem Lab Med. 2020.

14. National S-C-SAEG. Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. Lancet Infect Dis. 2020.

15. Pfluger LS, Bannasch JH, Brehm TT, Pfefferle S, Hoffmann A, Norz D, et al. Clinical evaluation of five different automated SARS-CoV-2 serology assays in a cohort of hospitalized COVID-19 patients. J Clin Virol. 2020;130:104549.

16. Arora RK, Joseph A, Van Wyk J, Rocco S, Atmaja A, May E, et al. SeroTracker: a global SARS-CoV-2 seroprevalence dashboard. Lancet Infect Dis. 2020.

17. Bailey D, Konforte D, Barakauskas VE, Yip PM, Kulasingam V, Abou El Hassan M, et al. Canadian society of clinical chemists (CSCC) interim consensus guidance for testing and reporting of SARS-CoV-2 serology. Clin Biochem. 2020.

18. Tang MS, Case JB, Franks CE, Chen RE, Anderson NW, Henderson JP, et al. Association between SARS-CoV-2 neutralizing antibodies and commercial serological assays. Clin Chem. 2020.

19. Turbett SE, Anahtar M, Dighe AS, Garcia Beltran W, Miller T, Scott H, et al. Evaluation of Three Commercial SARS-CoV-2 Serologic Assays and their Performance in Two-Test Algorithms. J Clin Microbiol. 2020.

20. Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Spijker R, Taylor-Phillips S, et al. Antibody tests for identification of current and past infection with SARS-CoV-2. Cochrane Database Syst Rev. 2020;6:CD013652.

21. Gattinger P, Borochova K, Dorofeeva Y, Henning R, Kiss R, Kratzer B, et al. Antibodies in serum of convalescent patients following mild COVID-19 do not always prevent virus-receptor binding. Allergy. 2020.

22. Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020;26(8):1200-4.

23. Baron RC, Risch L, Weber M, Thiel S, Grossmann K, Wohlwend N, et al. Frequency of serological non-responders and false-negative RT-PCR results in SARS-CoV-2 testing: a population-based study. Clin Chem Lab Med. 2020.

24. Wang J, Chen C, Li Q, Cai P, Wang Z, Wang L. COVID-19 confirmed patients with negative antibodies results. BMC Infect Dis. 2020;20(1):698.

25. Jung J, Garnett E, Jariwala P, Pham H, Huang R, Benzi E, et al. Clinical performance of a semi-quantitative assay for SARS-CoV2 IgG and SARS-CoV2 IgM antibodies. Clin Chim Acta. 2020;510:790-5.

26. Xu G, Emanuel AJ, Nadig S, Mehrotra S, Caddell BA, Curry SR, et al. Evaluation of Orthogonal Testing Algorithm for Detection of SARS-CoV-2 IgG Antibodies. Clin Chem. 2020.

27. Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahon M, et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med. 2020;26(7):1033-6.

28. Haslacher H, Gerner M, Hofer P, Jurkowitsch A, Hainfellner J, Kain R, et al. Usage Data and Scientific Impact of the Prospectively Established Fluid Bioresources at the Hospital-Based MedUni Wien Biobank. Biopreserv Biobank. 2018;16(6):477-82.

29. Breyer-Kohansal R, Hartl S, Burghuber OC, Urban M, Schrott A, Agusti A, et al. The LEAD (Lung, Heart, Social, Body) Study: Objectives, Methodology, and External Validity of the Population-Based Cohort Study. J Epidemiol. 2019;29(8):315-24.

30. Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahon M, et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nature Medicine. 2020;26(7):1033-6.

31. Favresse J, Eucher C, Elsen M, Tre-Hardy M, Dogne JM, Douxfils J. Clinical Performance of the Elecsys Electrochemiluminescent Immunoassay for the Detection of SARS-CoV-2 Total Antibodies. Clin Chem. 2020;66(8):1104-6.

32. Wang H, Ai J, Loeffelholz MJ, Tang YW, Zhang W. Meta-analysis of diagnostic performance of serology tests for COVID-19: impact of assay design and post-symptom-onset intervals. Emerg Microbes Infect. 2020;9(1):2200-11.

Captions

Fig. 1. A) *Testing algorithm utilizing a screening test on an automated platform (ECLIA/Roche, CMIA/Abbott, CLIA/DiaSorin) and a confirmation test, either on one of the remaining platforms or tested by means of ELISA (Technozym RBD, NP).* ***B)*** *All test results between a reduced cut-off suggested by the literature, and a higher cut-off, above which no more false-positive were observed, were subject to confirmation testing. *…for DiaSorin, no reasonable high cut-off could be defined, as false-positives were present nearly over the total range of the test (see Figure 2). [§]… suggested as a cut-off for seroprevalence testing; ¶… determined by in-house modeling; [1]… see (31); [2]…see (10); [3]… see (3).*

Fig. 2. *Results from the positive and the negative cohorts for automated platform assays (Roche, Abbott, DiaSorin). The grey zone covers all additional positive results yielded by applying a reduced cut-off (lower dashed line) instead of the cut-off suggested by the manufacturer (upper dashed line). For Roche and Abbott, a high cut-off could be defined, above which no more false-positives were observed (dotted line). Between the reduced and the high cut-off (if available), colored dots indicate samples that yielded positive results in more than one test system (red… one additional test; yellow… two additional tests; light green… three additional tests; blue… positive in all evaluated tests).*

Tbl.1. *Effect of applying reduced cut-offs derived from the literature (3, 10, 31) on sensitivities and specificities of automated platform assays. Green color indicates a significant gain, red color a significant reduction. PPV (2%)… Positive predictive value at*

2% estimated seroprevalence; NPV (2%)… Negative predictive value at 2% estimated seroprevalence; Δ… Difference.

Tbl. 2. *Effect of an orthogonal test strategy with reduced cut-offs. Resulting sensitivities and specificities are compared to those yielded if the respective single test is used as suggested by the manufacturer. Green color indicates a significant gain or a specificity of approximately 100.0% that could not be further improved. N… Number; PPV (2%)… Positive predictive value at 2% estimated seroprevalence; NPV (2%)… Negative predictive value at 2% estimated seroprevalence; Δ… Difference.*

Tbl. 3. *Possible combinations of screening (rows) and confirmation (columns) tests, both with reduced cut-offs, and resulting effects on sensitivity and specificity. ↑ significant increase, or a specificity of approximately 100.0% that could not be further improved; ⊥… no significant change.*

Suppl. Tbl. 1. *Effect of an orthogonal test strategy with the tests used as suggested by the manufacturer. Resulting sensitivities and specificities are compared to those yielded if the respective single test is used as suggested by the manufacturer. Green color indicates a significant gain, yellow color a specificity of approximately 100.0% that could not be further improved, and red color a significant loss. N… Number; PPV (2%)… Positive predictive value at 2% estimated seroprevalence; NPV (2%)… Negative predictive value at 2% estimated seroprevalence; Δ… Difference.*

Suppl. Tbl. 2. *Number of true-positives (top) and false-positives (bottom) after applying the proposed orthogonal testing strategy with reduced cut-offs. Technozym® RBD and NP (grey color) were used as confirmation tests only. Green cells and orange cells*

present the change in true- and false-positives, if only one test of the respective test with reduced cut-offs compared to manufacturer's cut-offs.

Suppl. Fig. 1. *Interdependence between positive predictive value (PPV) and prevalence at different specificities, while the sensitivity was kept at 90%.*

Figures and Tables

A

Fig.1



B

	Roche	Abbott	DiaSorin	Technozym RBD	Technozym NP
Cut-off (manufacturer)	1.000 COI	1.40 Index	12.0 AU/mL*	8.000 U/mL[§]	8.000 U/mL[§]
Reduced Cut-off	>0.165[1]	≥0.55[2]	≥9.0[3]	>4.000[¶]	>4.000[¶]
High Cut-off	3.000	3.00	-	-	-

Fig. 1. A) *Testing algorithm utilizing a screening test on an automated platform (ECLIA/Roche, CMIA/Abbott, CLIA/DiaSorin) and a confirmation test, either on one of the remaining platforms or tested by means of ELISA (Technozym RBD, NP).* ***B)*** *All test results between a reduced cut-off suggested by the literature, and a higher cut-off, above which no more false-positive were observed, were subject to confirmation testing. *…for DiaSorin, no reasonable high cut-off could be defined, as false-positives were present nearly over the total range of the test (see Figure 2). [§]… suggested as a cut-off for seroprevalence testing; ¶… determined by in-house modeling; [1]… see (31); [2]…see (10); [3]… see (3).*

Fig.2



Fig. 2. *Results from the positive and the negative cohorts for automated platform assays (Roche, Abbott, DiaSorin). The grey zone covers all additional positive results yielded by applying a reduced cut-off (lower dashed line) instead of the cut-off suggested by the manufacturer (upper dashed line). For Roche and Abbott, a high cut-off could be defined, above which no more false-positives were observed (dotted line). Between the reduced and the high cut-off (if available), colored dots indicate samples that yielded positive results in more than one test system (red… one additional test; yellow… two additional tests; light green… three additional tests; blue… positive in all evaluated tests).*

	Roche		Abbott		DiaSorin	
	Manufacturer's cut-off:	*Reduced cut-off:*	*Manufacturer's cut-off:*	*Reduced cut-off:*	*Manufacturer's cut-off:*	*Reduced cut-off:*
Cut-offs	**≥1.000 COI**	**>0.165 COI**	**≥1.40 Index**	**≥0.55 Index**	**≥12.0 AU/mL***	**≥9.0 AU/mL**
Sensitivity	*89.1 (79.1-94.6)*	*98.4 (91.7-99.7)*	*84.4 (73.6-91.3)*	*96.9 (89.3-99.1)*	*82.8 (71.8-90.1)*	*89.1 (79.1-94.6)*
Δ Sensitivity		*Z=+2.45, P=0.014*		*Z=+2.83, p=0.005*		*Z=+2.00, p=0.046*
Specificity	*99.7 (99.2-99.9)*	*98.4 (97.5-99.0)*	*99.2 (98.5-99.6)*	*97.6 (96.5-98.3)*	*98.2 (97.3-98.8)*	*97.2 (96.1-98.0)*
Δ Specificity		*Z=-3.87, P<0.001*		*Z=-4.24, p<0.0001*		*Z=-3.32, p<0.001*
PPV (2%)	*87.1 (68.5-95.5)*	*55.5 (44.1-66.4)*	*68.1 (52.5-80.5)*	*45.0 (36.0-54.3)*	*48.6 (37.6-59.6)*	*39.6 (31.4-48.4)*
NPV (2%)	*99.8 (99.5-99.9)*	*100.0 (99.8-100.0)*	*99.7 (99.4-99.8)*	*99.9 (99.7-100.0)*	*99.6 (99.4-99.8)*	*99.8 (99.5-99.9)*

Tbl.1. *Effect of applying reduced cut-offs derived from the literature (3, 10, 31) on sensitivities and specificities of automated platform assays. Green color indicates a significant gain, red color a significant reduction. PPV (2%)… Positive predictive value at 2% estimated seroprevalence; NPV (2%)… Negative predictive value at 2% estimated seroprevalence; Δ… Difference.*

Roche	**Manufacturer's cut-off:**	**Orthogonal testing with reduced cut-offs:**			
Cut-offs	**≥1.000 COI**	**>0.165 COI + RBD >4 U/mL**	**>0.165 COI + NP >4 U/mL**	**> 0.165 COI + Abbott ≥0.55 Index**	**>0.165 COI + DiaSorin ≥9.0 AU/mL**
N (%) retested		*27 (2.3%)*			
Sensitivity	*89.1 (79.1-94.6)*	*95.3 (87.1-98.4)*	*87.5 (77.2-93.4)*	*96.9 (89.3-99.1)*	*95.3 (87.1-98.4)*
Δ Sensitivity		*Z=+2.00, P=0.046*	*Z=-0.58, P=0.564*	*Z=+2.24, P=0.025*	*Z=+2.00, P=0.046*
Specificity	*99.7 (99.2-99.9)*	*100.0 (99.7-100.0)*	*100.0 (99.7-100.0)*	*100.0 (99.7-100.0)*	*100.0 (99.7-100.0)*
Δ Specificity		*Z=+1.73, P=0.083*	*Z=+1.73, P=0.083*	*Z=+1.73, P=0.083*	*Z=+1.73, P=0.083*
PPV (2%)	*87.1 (68.5-95.5)*	*100.0*	*100.0*	*100.0*	*100.0*
NPV (2%)	*99.8 (99.5-99.9)*	*99.9 (99.7-100.0)*	*99.7 (99.5-99.9)*	*99.9 (99.8-100.0)*	*99.9 (99.7-100.0)*

Abbott	**Manufacturer's cut-off:**	**Orthogonal testing with reduced cut-offs:**			
Cut-offs	**≥1.40 Index**	**≥0.55 I + RBD >4 U/mL**	**≥0.55 I + NP >4 U/mL**	**≥0.55 I + Roche >0.165 COI**	**≥0.55 I + DiaSorin ≥9.0 AU/mL**
N (%) retested		*45 (3.8%)*			
Sensitivity	*84.4 (73.6-91.3)*	*95.3 (87.1-98.4)*	*85.9 (75.4-92.4)*	*96.9 (89.3-99.1)*	*92.2 (83.0-96.6)*
Δ Sensitivity		*Z=+2.65, p=0.008*	*Z=+0.58, p=0.564*	*Z=+2.83, p=0.005*	*Z=+1.89, p=0.059*
Specificity	*99.2 (98.5-99.6)*	*99.8 (99.3-100.0)*	*99.8 (99.3-100.0)*	*100.0 (99.7-100.0)*	*99.9 (99.5-100.0)*
Δ Specificity		*Z=+2.33, p=0.020*	*Z=+2.13, p=0.020*	*Z=+3.00, p=0.003*	*Z=+2.83, p=0.005*
PPV (2%)	*68.1 (52.5-80.5)*	*91.6 (73.1-97.7)*	*90.7 (71.0-97.5)*	*100.0*	*95.5 (74.7-99.3)*
NPV (2%)	*99.7 (99.4-99.8)*	*99.9 (99.7-100.0)*	*99.7 (99.5-99.8)*	*99.9 (99.8-100.0)*	*99.8 (99.6-99.9)*

DiaSorin	**Manufacturer's cut-off:**	**Orthogonal testing with reduced cut-offs:**			
Cut-offs	**≥12.0 AU/mL***	**≥9.0 AU/mL + RBD >4 U/mL**	**≥9.0 AU/mL + NP >4 U/mL**	**≥9.0 AU/mL + Roche >0.165 COI**	**≥9.0 AU/mL + Abbott ≥0.55 Index**
N (%) retested		*87 (7.4%)***			
Sensitivity	*82.8 (71.8-90.1)*	*87.5 (77.2-93.5)*	*79.7 (68.3-87.7)*	*88.9 (78.8-94.5)*	*87.5 (77.2-93.5)*
Δ Sensitivity		*Z=+1.34, p=0.180*	*Z=-0.71, p=0.480*	*Z=+2.00, p=0.046*	*Z=+1.34, p=0.180*
Specificity	*98.2 (97.3-98.8)*	*99.9 (99.5-100.0)*	*100.0 (99.7-100.0)*	*100.0 (99.7-100.0)*	*99.9 (99.5-100.0)*
Δ Specificity		*Z=+4.36, p<0.0001*	*Z=+4.47, p<0.0001*	*Z=+4.47, p<0.0001*	*Z=+4.36, p<0.0001*
PPV (2%)	*48.6 (37.6-59.6)*	*95.2 (73.7-99.3)*	*100.0*	*100.0*	*95.2 (73.7-99.3)*
NPV (2%)	*99.6 (99.4-99.8)*	*99.7 (99.5-99.9)*	*99.6 (99.3-99.7)*	*99.8 (99.6-99.9)*	*99.7 (99.5-99.9)*

Tbl. 2. *Effect of an orthogonal test strategy with reduced cut-offs. Resulting sensitivities and specificities are compared to those yielded if the respective single test is used as suggested by the manufacturer. Green color indicates a significant gain or a specificity of approximately 100.0% that could not be further improved. N… Number; PPV (2%)… Positive predictive value at 2% estimated seroprevalence; NPV (2%)… Negative predictive value at 2% estimated seroprevalence; Δ… Difference.*

Confirmation / Screening	Roche Elecsys® (NC, total)		Abbott ARCHITECT (NC, IgG)		DiaSorin (S1/S2, IgG)		Technozym® RBD (RBD, IgG)		Technozym® NP (NC, IgG)	
	Sensitivity	Specificity	Sensitivity	Specificity	Sensitivity	Specificity	Sensitivity	Specificity	Sensitivity	Specificity
Roche Elecsys® (NC, total)			↑	↑	↑	↑	↑	↑	⊥	↑
Abbott ARCHITECT (NC, IgG)	↑	↑			⊥	↑	↑	↑	⊥	↑
DiaSorin (S1/S2, IgG)	↑	↑	⊥	↑			⊥	↑	⊥	↑

Tbl. 3. *Possible combinations of screening (rows) and confirmation (columns) tests, both with reduced cut-offs, and resulting effects on sensitivity and specificity. ↑ significant increase, or a specificity of approximately 100.0% that could not be further improved; ⊥… no significant change.*